Impact of visceral obesity on clinical outcome and quality of life for patients with multiple myeloma: A secondary data analysis of STaMINA (BMT CTN 0702) trial Journal Article
| Authors: | Malek, E.; Kort, J.; Metheny, L.; Fu, P.; Li, G.; Hari, P.; Efebera, Y.; Callander, N. S.; Qazilbash, M. H.; Giralt, S.; Krishnan, A.; Stadtmauer, E. A.; Lazarus, H. M. |
| Article Title: | Impact of visceral obesity on clinical outcome and quality of life for patients with multiple myeloma: A secondary data analysis of STaMINA (BMT CTN 0702) trial |
| Abstract: | Obesity is a common health problem in patients with multiple myeloma (MM) that has been linked to poor clinical outcomes and quality of life (QoL). We conducted a secondary analysis of the BMT CTN 0702, a randomized, controlled trial comparing outcomes of 3 treatment interventions after a single hematopoietic cell transplantation (HCT) (n = 758), to investigate the impact of visceral obesity, as measured by waist-to-hip ratio (WHR), on clinical outcomes and QoL in MM patients. A total of 549 MM patients, median age 55.5 years, were enrolled in the study. The majority of patients received triple-drug antimyeloma initial therapy before enrollment, and 29% had high-risk disease according to cytogenetic assessment. The median duration of follow-up was 6 years. There was no significant association between WHR and progression-free survival (PFS) or overall survival (OS) in MM patients undergoing HCT. Similarly, body mass index (BMI) did not significantly predict PFS or OS. Furthermore, there was no significant correlation between WHR and QoL measures. This study suggests that visceral obesity, as measured by WHR, might not have a significant impact on clinical outcomes in MM patients undergoing HCT. These findings add to the existing literature on the topic and provide valuable information for healthcare professionals and MM patients. Further studies are needed to confirm these results and to investigate other potential factors that may affect clinical outcomes and QoL in this patient population using modern imaging technologies to assess visceral obesity. © 2024 |
| Keywords: | adult; cancer survival; controlled study; treatment outcome; aged; middle aged; major clinical study; overall survival; lenalidomide; antineoplastic agent; prospective study; progression free survival; quality of life; bortezomib; multiple myeloma; randomized controlled trial; obesity; cytogenetics; cyclophosphamide; dexamethasone; melphalan; hematopoietic stem cell transplantation; body mass; waist hip ratio; body mass index; fluorescence in situ hybridization; karnofsky performance status; phase 3 clinical trial; abdominal obesity; short form 36; bone marrow transplantation; therapy; hematopoietic cell transplantation; functional assessment of cancer therapy; clinical outcome; humans; human; male; female; article; obesity, abdominal; physical well-being; emotional well-being; secondary data analysis |
| Journal Title: | Transplantation and Cellular Therapy |
| Volume: | 30 |
| Issue: | 7 |
| ISSN: | 2666-6375 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-07-01 |
| Start Page: | 698.e1 |
| End Page: | 698.e10 |
| Language: | English |
| DOI: | 10.1016/j.jtct.2024.01.053 |
| PUBMED: | 38244697 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
